You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

glucagon-like peptide-1

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Glucagon-like Peptide-1 Receptor Agonists According to Type 2

Recruiting
  • Diabetes Mellitus, Type 2
  • GLP-1 receptor agonist
  • Bari, Italy
    Azienda Ospedaliero-Universitaria Policlinico Bari
Nov 4, 2023

Caveolin 1 Deficiency in Response to Glucagon-like Peptide 1

Not yet recruiting
  • Overweight and Obesity
  • 24-hour ambulatory blood pressure
  • Liberal salt diet
  • (no location specified)
Oct 4, 2023

Preoperative Prandial State of Patients Taking Glucagon-Like

Recruiting
  • Pulmonary Aspiration
  • Gastric ultrasound
  • Houston, Texas
    The University of Texas Health Science Center at Houston
Jun 6, 2023

Effects of Glucagon-like-Peptide-1 Analogues on Sexuality

Recruiting
  • Sexual Desire
    • Basel, Switzerland
      University Hospital Basel, Endocrinology, Diabetes and Metabolis
    Nov 28, 2022

    Stroke, Stroke, Acute, Stroke, Ischemic Trial in Linyi, Hong Kong (Semaglutide)

    Recruiting
    • Stroke
    • +3 more
    • Linyi, Shangdong, China
    • +1 more
    Jun 24, 2023

    Gastric Ultrasound Assessment for Patients Taking GLP1 Agonists

    Not yet recruiting
    • Gastric Ultrasound
    • +2 more
    • Gastric Ultrasound Exam
    • (no location specified)
    Aug 15, 2023

    Glucagon-like Peptide 1 Receptor Agonists and Mental Health

    Not yet recruiting
    • Diabetes Mellitus
    • +2 more
    • GLP-1 receptor agonist
    • (no location specified)
    Aug 4, 2022

    Type1 Diabetes Trial in Baltimore (Glucagon-like peptide-1, Placebos)

    Recruiting
    • Type1 Diabetes Mellitus
    • Glucagon-like peptide-1
    • Placebos
    • Baltimore, Maryland
      University of Maryland
    Apr 8, 2022

    Non-Alcoholic Fatty Liver Disease, Non-alcoholic Steatohepatitis, Type 2 Diabetes Trial in Al Ain (GIP/GLP-1a)

    Not yet recruiting
    • Non-Alcoholic Fatty Liver Disease
    • +3 more
    • Al Ain, Abu Dhabi, United Arab Emirates
      Internal Medicine, College of Medicine and Health Sciences
    Mar 1, 2023

    Asthma Trial in Nashville (Semaglutide Pen Injector 2.4mg weekly, Placebo)

    Not yet recruiting
    • Asthma
    • Semaglutide Pen Injector 2.4mg weekly
    • Placebo
    • Nashville, Tennessee
      Vanderbilt University Medical Center
    Jun 22, 2022

    Sexual Functioning Trial in Basel (Dulaglutide, Placebo)

    Recruiting
    • Sexual Functioning
    • Basel, Switzerland
      University Hospital Basel, Endocrinology, Diabetes and Metabolis
    Mar 3, 2022

    A Pan-European Post-Authorisation Safety Study: Risk of

    Not yet recruiting
    • Pancreatic Cancer
    • Exenatide
    • Non-GLP-1 RA based glucose lowering drugs
    • (no location specified)
    Dec 21, 2022

    Wolfram Syndrome Trial (Tirzepatide)

    Not yet recruiting
    • Wolfram Syndrome
    • (no location specified)
    Dec 12, 2022

    Obesity Trial in Mansourah, Mansoura (Liraglutide)

    Recruiting
    • Obesity
    • Mansourah, Dakhlia, Egypt
    • +1 more
    Feb 24, 2022

    GLP-1RAs) and SGLT2is Combination Therapy and MACEs in Type 2

    Recruiting
    • Diabetes Mellitus, Type 2
    • Myocardial Infarction
    • PCI
    • Naples, Italy
      Celestino Sardu
    Aug 31, 2023

    Cardiovascular Diseases Trial in Cambridge (Saline 0.9%, Glucagon (25ng/kg/min), Glucagon (50ng/kg/min))

    Recruiting
    • Cardiovascular Diseases
    • Saline 0.9%
    • +3 more
    • Cambridge, Cambridgeshire, United Kingdom
      Addenbrooke's Hospital
    Dec 10, 2021

    Effects of GLP-1 Agonists on Gastric Volume

    Not yet recruiting
    • Diabetes
    • +3 more
    • Gastric Ultrasound
    • Charleston, South Carolina
      Medical University of South Carolina
    May 10, 2023

    Kidney Transplant Recipients Trial in Toronto (Dapagliflozin 10 MG, Semaglutide, 1.0 mg/mL)

    Not yet recruiting
    • Kidney Transplant Recipients
    • Dapagliflozin 10 MG
    • Semaglutide, 1.0 mg/mL
    • Toronto, Ontario, Canada
      Toronto General Hospital
    Jul 6, 2023

    Alcohol Abuse, Alcohol Addiction, Alcohol Dependence Trial in Frederiksberg (Semaglutide Injectable Product, Placebo)

    Recruiting
    • Alcohol Abuse
    • +3 more
    • Semaglutide Injectable Product
    • Placebo
    • Frederiksberg, Denmark
      Psychiatric Center Copenhagen, Frederiksberg Hospital
    Jun 13, 2023

    Type 2 Diabetes in Obese Trial in Derby (Semaglutide Pen Injector [Ozempic], Very-low Calorie Diet)

    Recruiting
    • Type 2 Diabetes Mellitus in Obese
    • Semaglutide Pen Injector [Ozempic]
    • Very-low Calorie Diet
    • Derby, United Kingdom
      University of Nottingham, Royal Derby Hospital Centre
    Oct 31, 2022

    Obesity, Childhood, Neural Development Trial in New Haven (Liraglutide)

    Completed
    • Obesity, Childhood
    • Neural Development
    • New Haven, Connecticut
      Yale University
    Dec 5, 2022

    Diabetes, Diabetic Kidney Disease Trial in Sha Tin (Dulaglutide, Insulin Degludec, Continuous glucose monitor)

    Recruiting
    • Diabetes Mellitus
    • Diabetic Kidney Disease
    • Sha Tin, Hong Kong
      Prince of Wales Hospital
    Nov 8, 2022

    Parkinson's Disease Trial in Gainesville (Exenatide)

    Completed
    • Parkinson's Disease
    • Gainesville, Florida
      Laboratory for Rehabilitation Neuroscience
    Sep 14, 2022

    Type 2 Diabetes, Obesity Trial in Cambridge (0.9% Sodium-chloride, Exenatide (50ng/min for 30 minutes loading followed by

    Recruiting
    • Type 2 Diabetes
    • Obesity
    • 0.9% Sodium-chloride
    • +3 more
    • Cambridge, Cambridgeshire, United Kingdom
      Cambridge University Hospitals NHS Foundation Trust and The Univ
    Jan 18, 2022

    Anti-obesity Pharmacotherapy and Inflammation

    Not yet recruiting
    • Obesity
    • Liraglutide or Semaglutide
    • Phentermine-Topiramate combination
    • New Orleans, Louisiana
    • +1 more
    Mar 3, 2023